Advancing Precision Medicine: Challenges and Opportunities for Universal Access to Innovative Therapies
Verónica Sotomayor
Driving Innovation in Healthcare | Leader in Precision Medicine | Business Strategist | Consultant & Advisor | Career Mentor | PhD MBA MSc
While reading the review "The evolving landscape on Tissue-agnostic therapies in precision oncology", I felt motivated to express some thoughts and concepts in this short article. The paper effectively summarizes the current status of tissue-agnostic therapies, which target genetic mutations rather than solely focusing on tumor location, and highlights their significant role in advancing precision oncology.
While this paper focuses on precision oncology, many of the concepts can be extrapolated to several other diseases. As we gather more and more comprehensive patient data, each disease will become increasingly unique, potentially leading to more precise and effective treatment protocols. While this represents a promising advancement, there are still numerous challenges that need to be addressed to ensure that every patient can benefit from innovation:
?? Ensuring timely access to advanced diagnostics is crucial for identifying actionable biomarkers, which in turn facilitates tailoring treatments to individual patients. This approach can improve outcomes, reduce side effects, and optimize the utilization of healthcare resources.
?? Insights obtained from the rare diseases approach can be highly beneficial in devising strategies, such as patient identification, and offer invaluable knowledge and experience to many other diseases.
?? The current wave of clinical trials for novel therapies increasingly focuses on a wider array of biomarkers, well-known markers, and newly discovered ones, offering a more holistic approach to understanding and treating diseases. In this scenario, the requirement for innovative and increasingly inclusive clinical research arises.
?? Despite the advancements, ensuring equitable access to innovative therapies remains a challenge. Efforts must be made to overcome barriers related to cost, availability of advanced diagnostics, and healthcare infrastructure.
领英推荐
?? Collaboration among researchers, clinicians, payers, pharmaceutical companies, and patient advocates, among others, is vital to stimulate further innovation and guarantee the accessibility of state-of-the-art treatments to all patients.
In conclusion, embracing the principles of precision medicine holds the potential to revolutionize healthcare, offering tailored treatments and improved outcomes for patients across diverse medical conditions.
Subbiah, V., Gouda, M. A., Ryll, B., Burris, H. A., & Kurzrock, R. (2024). The evolving landscape of tissue‐agnostic therapies in precision oncology. CA: A Cancer Journal for Clinicians. DOI: 10.3322/caac.21844
#PrecisionOncology #TissueAgnosticTherapies #RareDiseases #MedicalInnovation #Access #Equity #Collaboration
Directora del departamento de inmunopatología en Alexander Fleming
10 个月Thank you Verònica! Excellent comment about precision medicine. “Equitable access to innovative therapies remains a challenge. Efforts must be made to overcome barriers related to cost, availability of advanced diagnostics, and healthcare infrastructure” is crucial in this article. In LATAM WE must make all efforts, to give the chance to our patients, to have the best approach to their diseases.
Gerente de Relaciones Científico Institucionales
10 个月Muy bueno Verónica Sotomayor. Colaborar entre los distintos sectores para brindar al paciente y su familia un soporte abarcativo, es fundamental.
Chief Medical Officer Biotech / Medical affairs and clinical development director / Public-private partnership in science & biotech / Women leadership/Health biotech advisor
10 个月Verónica, you are adressing the most relevant points that should drive research in the very fast evolving current landscape. It would be interesting to see more public-private collaboration in this field. Great article! Thanks, Verónica Sotomayor
Medical Manager - Hepatologist and Internal Medicine External Offices-Principal Investigator -MBA.
10 个月Excellent Vero! I believe that one of the most relevant points from which all actors involved in the treatment must focus is on collaboration, putting the patient as the focus to have better outcomes including not only health results but also the economic implications that this generate
Guiding Companies enter the Regulated US and Latin America Markets. US Agent for FDA. Regulatory and R&D Consultant for LATAM&USA. FDA&EMA Biologics Expert. Speaker for AI. CEO & CoFounder - Bioxentys and Pharma 4.0
10 个月Excelente mirada Verónica Sotomayor